SuperworthRocket Pharmaceuticals market cap RCKT
Share price times shares outstanding: what the whole company sells for, since 2015.
- Today, Oct 23, 2026
- $251.4M
- Highest close in our data
- $3.5B
- Feb 2021
Rocket Pharmaceuticals is worth $251.4M at the close on Oct 23, 2026, at $2.29 a share.
That is down 39% over the last year and down 87% over five years.
Its highest close in our data was $3.5B in Feb 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $251.4M | $239.3M | $543.9M | −33% |
| 2025 | $376.6M | $270.4M | $1.1B | −65% |
| 2024 | $1.1B | $1.1B | $2.8B | −60% |
| 2023 | $2.7B | $1.2B | $2.7B | +82% |
| 2022 | $1.5B | $598.5M | $1.7B | +5% |
| 2021 | $1.4B | $1.4B | $3.5B | −54% |
| 2020 | $3B | $715.4M | $3.3B | +150% |
| 2019 | $1.2B | $546.3M | $1.2B | +109% |
| 2018 | $579.6M | $83.6M | $976.5M | +716% |
| 2017 | $71.1M | $25.1M | $74.6M | −57% |
| 2016 | $164.3M | $161.6M | $275.3M | −45% |
| 2015 | $299.2M | $78.5M | $313.5M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Rocket Pharmaceuticals' size, closest first, today.
| Company | Market cap |
|---|---|
| RCKTRocket Pharmaceuticals | $251.4M |
| NATRNatures Sunshine Products | $213.8M |
| ARVNArvinas | $477.3M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| COLLCollegium Pharmaceutical | $747.5M |
| ABUSArbutus Biopharma | $831M |
| LFVNLifevantage | $73.4M |
| SPROSpero Therapeutics | $64.6M |
| Peer median | $570.3M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Rocket Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.